Company intelligence / Profile preview

Intalight

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Intalight’s DREAM OCT™ platform provides ultra-wide, multimodal imaging with deep penetration and rapid scanning for ophthalmic diagnosis and research. It is CE marked and commercially available in the EU, pending FDA approval in the US. Over 170 peer-reviewed publications have utilized its technology, including studies on proliferative diabetic retinopathy.

Therapeutic areas: Ophthalmology
Modalities: Device
Industry: Medical Imaging

Partnerships

Adapt (Brazil distribution)academic collaborations with top retina institutions in the US, Europe, and Asia

Beyond the preview

Go deeper on Intalight.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Intalight.

Explore the full profile